Literature DB >> 10561146

Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders.

W Y Au1, K W Chan, S L Lui, C C Lam, Y L Kwong.   

Abstract

The myeloproliferative disorders (MPDs) are clonal disorders of the hematopoietic stem cell and classified as polycythemia vera (PV), essential thrombocythemia (ET), or agnogenic myeloid metaplasia (AMM), depending on the main hematopoietic lineage involved. Primary renal parenchymal lesions are not commonly reported in these cases. We conducted a retrospective analysis of 138 consecutive patients with MPD to determine the frequency of renal parenchymal complications. Five patients (3.6%) (two PV, two ET, one AMM) were found to have focal segmental glomerulosclerosis (FSGS) and diffuse mesangial sclerosis, presenting as proteinuria in all the cases and progressing to chronic renal failure in two cases. A possible common risk factor was a high platelet count, because abnormal platelet activation in MPD has been shown to contribute to the development of glomerulosclerosis. The pathophysiologic basis of our observations and the implications in management of MPD patients remain to be studied.

Entities:  

Mesh:

Year:  1999        PMID: 10561146     DOI: 10.1016/S0272-6386(99)70047-8

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Nat Rev Nephrol       Date:  2010-12-14       Impact factor: 28.314

2.  WITHDRAWN: Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol       Date:  2017-07-24       Impact factor: 0.975

Review 3.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

4.  Polycythemia vera associated with IgA nephropathy: A case report and literature review.

Authors:  Hong Chen; Baohe Zhang; Mingxu Li; Ruilan Hu; Chunhua Zhou
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

5.  Focal segmental glomerulosclerosis associated with essential thrombocythemia.

Authors:  Kazutaka Haraguchi; Hiroki Shimura; Ryouji Ogata; Hironobu Inoue; Takehiro Saito; Tetsuo Kondo; Michio Nagata; Tetsuro Kobayashi
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

6.  Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.

Authors:  Gian Marco Ghiggeri; Luca Musante; Giovanni Candiano; Maurizio Bruschi; Laura Santucci; Giancarlo Barbano; Antonella Trivelli; Lucia Rivabella; Rosanna Gusmano; Francesco Perfumo
Journal:  Pediatr Nephrol       Date:  2007-07-28       Impact factor: 3.714

7.  Crescentic Glomerulonephritis Associated with Polycythaemia Vera: A Rare Occurrence.

Authors:  Rohan Dwivedi; K B Shashikiran; Sonu Manuel; Faizan A Ansari; Sree B Raju
Journal:  Indian J Nephrol       Date:  2022-03-09

8.  Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era.

Authors:  Rachele Del Sordo; Rachele Brugnano; Carla Covarelli; Gioia Fiorucci; Franca Falzetti; Giorgio Barbatelli; Emidio Nunzi; Angelo Sidoni
Journal:  Clin Nephrol Case Stud       Date:  2017-07-24

9.  Renal biopsy cases in myeloproliferative neoplasms (MPN).

Authors:  Kumi Fujita; Kazuhiro Hatta
Journal:  CEN Case Rep       Date:  2013-03-12

10.  A Case of Essential Thrombocythemia and IgA Nephropathy with Literature Review of the Concurrence.

Authors:  Shoja Rahimian; Timothy Johnson; Ronald Herb
Journal:  Case Rep Oncol Med       Date:  2019-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.